Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024
June 25, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Tonix’s live virus vaccine TNX-801 is designed to provide long-term protection from mpox and smallpox with one dose TNX-801 vaccination demonstrated efficacy in protecting animals from lethal...
Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia
June 20, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Company aligned with FDA on key CMC topics Tonix also has completed the second and final pre-New Drug Application (NDA) meeting and discussed nonclinical, clinical pharmacology and clinical matters...
Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS)
June 18, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Gap in non-oral prescriptions relative to AHS guidelines represents an opportunity to increase awareness of Tonix’s two FDA-approved non-oral treatments for acute migraine Zembrace® SymTouch®...
Tonix Pharmaceuticals Presented Poster of Tonmya™ for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024
June 17, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Treatment with Tonmya™ (TNX-102 SL, sublingual cyclobenzaprine HCl) in Phase 3 RESILIENT study significantly reduced daily pain and demonstrated broad fibromyalgia symptom improvement, as demonstrated...
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
June 13, 2024 17:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the...
Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
June 12, 2024 09:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has...
Tonix Pharmaceuticals Announces Proposed Public Offering
June 11, 2024 17:17 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it...
Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split
June 06, 2024 11:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), fully-integrated biopharmaceutical company with marketed products and a...
Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024
June 06, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-1500 displays potential as a monotherapy or combination therapy to prevent rejection in organ transplantation in allograft and xenograft animal models Research Directed by Faculty of the...
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024
June 05, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Presentation to highlight statistically significant Phase 3 results of Tonmya™ (TNX-102 SL) for the management of fibromyalgia New Drug Application (NDA) submission to the FDA on track...